The Lung Cancer Diagnostic And Screening Market, estimated at USD 3,287.8 Mn in 2026, is expected to exhibit a CAGR of 10.3% and reach USD 6,530.4 Mn by 2033.
The market growth is driven by rising demand for accurate and early disease detection, supported by advances in molecular diagnostics, imaging, and point-of-care testing. Growing focus on personalized medicine, supportive healthcare policies, and ongoing R&D investments are creating new opportunities for industry players.
Key market players are focusing on adopting growth strategies such as collaborations, which will drive the global lung cancer diagnostic and screening market. For instance, on May 9, 2023, Pfizer Inc., a company that discovers, develops, manufactures, and commercializes biopharmaceuticals, and Thermo Fisher Scientific Inc., a biotechnology and laboratory equipment company, announced that they had entered into a collaboration agreement to help increase local access to next-generation sequencing (NGS)-based testing for lung and breast cancer patients.
Global Lung Cancer Diagnostic and Screening Market: Key Developments
- In June 2026, Biomedical engineers at UConn have received NIH R33 funding to develop a programmable, smartphone-based diagnostic platform aimed at improving early lung cancer screening. The technology integrates CRISPR-based molecular detection with liquid biopsy methods to identify cancer-related mutations in blood samples. By making testing faster, less invasive, and more accessible, the innovation seeks to strengthen early detection rates and improve patient outcomes, especially by enabling affordable, point-of-care screening for high-risk populations globally. (Source: University of Connecticut)
- In June 2026, ChristianaCare, provider of outpatient laboratory services and Lisen Imprinting Diagnostics launched a research collaboration to improve lung cancer diagnosis using advanced molecular imaging technology. The study will evaluate LisenID’s QCIGISH platform to detect early cancer-related genetic changes in biopsy samples, especially in cases where results are unclear or tissue is limited. This initiative aims to enhance diagnostic accuracy, reduce uncertainty in clinical decision-making, and enable earlier, more precise detection of lung cancer in high-risk patients. (Source: ChristianaCare)
- On March 21, 2023, AstraZeneca, a multinational pharmaceutical and biotechnology company, announced that it had signed a Memorandum of Understanding (MoU) with Phyathai 2 Hospital to use AI-based technology for chest X-rays in the hospital to enhance the diagnosis of early-stage lung cancer.
- On March 13, 2023, University of Buffalo., a public university, announced that it is developing a new lung cancer screening test and has secured US$3.5 million to create a liquid biopsy test that could help detect cancer earlier and improve treatment.
- In March 2022, OPTELLUM INC., an Oxford-based medtech company that provides breakthrough AI technologies to help with early diagnosis of lung cancer, announced that it had attained CE marking for its Virtual Nodule Clinic, an AI-powered clinical decision support software that helps clinicians identify and track at-risk patients who present suspicious lung nodules that may or may not be cancerous.
Browse 35 Market Data Tables and 31 Figures spread through 180 Pages and in-depth TOC on “Global Lung Cancer Diagnostic and Screening Market”- Forecast to 2033, Global Lung Cancer Diagnostic and Screening Market, By Product [Biomarkers Test (EGFR Mutation Test, KRAS Mutation Test, ALK Test, Others), Imaging Test (Computed Tomography (CT) scan, Positron Emission Tomography (PET) scan, Chest X-Ray, Others), Biopsy], By Cancer Type (Non-small cell lung cancer and Small Cell Lung Cancer), By End User (Hospital Associated Labs, Independent Diagnostic Laboratories, Cancer Research Institutes and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa).
To know the latest trends and insights prevalent in this market, click the link below:
Key Takeaways of the Global Lung Cancer Diagnostic and Screening Market
- The global lung cancer diagnostic and screening market is expected to exhibit a CAGR of 10.1% during the forecast period. The merger with emerging economies offers lucrative growth opportunities for players in the global lung cancer diagnostic and screening market.
- Among cancer type, the non-small cell lung cancer segment is expected to hold a dominant position in the global lung cancer diagnostic and screening market during the forecast period, and this is attributed to the increase in the prevalence of non-small cell lung cancer. For instance, in February 2022, 2.2 million people were diagnosed globally with lung cancer in 2020, with non-small cell lung cancer accounting for approximately 85 percent of all lung cancer patients. As a result of the availability of a wide patient base and the growing number of non-small cell lung cancer patients, there is a significant need for therapy to treat the patients.
- Among region, North America is expected to be the dominant region in the global lung cancer diagnostic and screening market, owing to the increasing prevalence of lung cancer. For instance, in January 2023, according to the American Cancer Society, a nationwide voluntary health organization dedicated to eliminating cancer, about 238,340 new cases of lung cancer (117,550 in men and 120,790 in women) and about 127,070 deaths from lung cancer (67,160 in men and 59,910 in women) were estimated in U.S. in the year 2023.
- Major players operating in the global lung cancer diagnostic and screening market are Abbott, Amgen Inc., Illumina, Inc., Thermo Fisher Scientific Inc., Lepu Medical Technology (Beijing)Co.,Ltd., AstraZeneca, F. Hoffmann-La Roche Ltd, Laboratory Corporation of America Holdings., Agilent Technologies, Inc., QIAGEN, Quest Diagnostics Incorporated., NeoGenomics Laboratories., Myriad Genetics, Inc., GRAIL, LLC., DELFI Diagnostics.
Contact Us